Status:
COMPLETED
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Lead Sponsor:
Eyetech Pharmaceuticals
Collaborating Sponsors:
Pfizer
Conditions:
Retinal Vein Occlusion
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S....
Detailed Description
This study will consist of 3 phases: a screening phase which will last up to two weeks, a confirmation phase which will last one day, and a randomization phase (the patient will be assigned by chance ...
Eligibility Criteria
Inclusion
- CRVO must have occurred within the past 6 months and be associated with macular edema determined by OCT.
- Vision in the study eye corresponding to between approximately 20/50 to 20/400 and better than or equal to approximately 20/200 in the fellow eye.
Exclusion
- Presence of signs of old branch retinal vein occlusion (BRVO) or CRVO in the study eye or any other retinal vascular disease including diabetic retinopathy.
- Vitreous hemorrhage except breakthrough hemorrhage from intraretinal hemorrhage.
- Prior pan retinal photocoagulation (PRP) or sector scatter photocoagulation.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00088283
Start Date
May 1 2004
Last Update
January 19 2007
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Centers, P.C., Northwest Location
Tucson, Arizona, United States, 85704
2
Retina Associates, SW
Tucson, Arizona, United States, 85710
3
Jules Stein Institute
Los Angeles, California, United States, 90095
4
Orange County Retina Associates
Santa Ana, California, United States, 92705